Mineralys Therapeutics, Inc. (MLYS) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
MLYS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Mineralys Therapeutics, Inc. (MLYS) trades at a price-to-earnings ratio of -12.8x, with a stock price of $29.35 and trailing twelve-month earnings per share of $-1.83.
Compared to the Healthcare sector median P/E of 22.3x, MLYS trades at a 157% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, MLYS trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MLYS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MLYS P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 62.3 | - | -33% | |
| $2B | 6.9 | 0.67Best | +817%Best | |
| $1B | 177.5 | - | -79% | |
| $490M | 28.3 | 2.12 | +188% | |
| $213M | 1.2Lowest | - | +472% | |
| $8B | 25.5 | 1.11 | -25% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See MLYS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MLYS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MLYS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMLYS — Frequently Asked Questions
Quick answers to the most common questions about buying MLYS stock.
Is MLYS stock overvalued or undervalued?
MLYS current P/E: -12.8x. 5-year average P/E: N/A. Percentile: N/A.
How does MLYS's valuation compare to peers?
Mineralys Therapeutics, Inc. P/E of -12.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is MLYS's PEG ratio?
MLYS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.